Silexion Therapeutics Ltd.
NASDAQ: SLXN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ilan Hadar
- Employees
- 11
- Headquarters
- Jerusalem, Israel
- IPO year
- 2024
- Market cap
- $1.1M
- Website
- https://silexion.com
Loading SLXN…
Loading profile data…Frequently asked questions about SLXN
What does Silexion Therapeutics Ltd. (SLXN) do?
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its...
Where does SLXN trade?
Silexion Therapeutics Ltd. (SLXN) trades on the NASDAQ Global Market.
What sector is SLXN in?
Silexion Therapeutics Ltd. (SLXN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Silexion Therapeutics Ltd.?
Ilan Hadar is the chief executive officer of Silexion Therapeutics Ltd. (SLXN).
Where is Silexion Therapeutics Ltd. headquartered?
Silexion Therapeutics Ltd. is headquartered in Israel.
Does SLXN pay a dividend?
Silexion Therapeutics Ltd. (SLXN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SLXN go public?
Silexion Therapeutics Ltd. (SLXN) completed its initial public offering in 2024.